Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Kidney Int. 2014 Oct 29;87(4):828–838. doi: 10.1038/ki.2014.350

Figure 3.

Figure 3

Percentage of CD3 T cells, CD4 T cells, CD8 T cells, effector CD4 T cells (CD4+CD25−), naïve CD4 T cells (CD4+CD45RA+), memory CD4 T cells (CD4+CD45RO+), naïve CD8 T cells (CD8+CD45RA+) and memory CD8 T cells (CD8+CD45RO+) in PBMC (Mean ± SD) at baseline, 6 months, 12 months and 24 months post-randomization comparing between TAC maintained and SRL converted group. SRL conversion did not result in changes of these T cell subpopulations. TAC, Tacrolimus maintained group; SRL Sirolimus converted group.

HHS Vulnerability Disclosure